EP2654737B1 - Novel preparation of an enteric release system - Google Patents

Novel preparation of an enteric release system Download PDF

Info

Publication number
EP2654737B1
EP2654737B1 EP11808505.9A EP11808505A EP2654737B1 EP 2654737 B1 EP2654737 B1 EP 2654737B1 EP 11808505 A EP11808505 A EP 11808505A EP 2654737 B1 EP2654737 B1 EP 2654737B1
Authority
EP
European Patent Office
Prior art keywords
enteric
percent
shellac
combination
hydrophobic liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11808505.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2654737A1 (en
Inventor
Ahmad Akashe
Anilkumar Ganapati Gaonkar
Les Lawrence
Amado R. Lopez
George W. Haas
Dana Sebesta
Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercontinental Great Brands LLC
Original Assignee
Intercontinental Great Brands LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercontinental Great Brands LLC filed Critical Intercontinental Great Brands LLC
Publication of EP2654737A1 publication Critical patent/EP2654737A1/en
Application granted granted Critical
Publication of EP2654737B1 publication Critical patent/EP2654737B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A23L27/72—Encapsulation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the present application relates to methods for microencapsulating a hydrophobic liquid with an enteric matrix substantially free of organic solvents. More particularly, the hydrophobic liquid is microencapsulated in an aqueous environment.
  • Enteric delivery of active materials in food delivery applications has been limited. Enteric delivery systems are commonly utilized when the active materials or medicaments are known to be sensitive to low pH or have undesirable flavor and/or taste characteristics which cannot be effectively masked by other methods. Generally, enteric delivery is accomplished using coated tablets and gel capsules. However, those particular delivery methods are not well suited for food applications. In particular, neither tablets nor capsules are sized to be integrated into most existing food products.
  • enteric delivery is microencapsulation.
  • Enteric microencapsulation is generally performed using specialized equipment or in an environment including organic solvents. These methods require additional capital expenditures and the use of additional materials, such as the organic solvents, which may or may not be usable in subsequent microencapsulation cycles. As a result, the process of microencapsulation requires investments in both equipment and organic solvent procurement and disposal.
  • US2010310726 relates to a novel preparation of an enteric release system.
  • WO0238181 relates to medicaments comprising a microbicidal composition consisting of at least two GRAS (Generally Recognized As Safe) aromatic agents or derivatives thereof.
  • GRAS Generally Recognized As Safe
  • WO0036924 relates to the use of N-[N-(3,3- dimethylbutyl) -L- alpha -aspartyl]-L-phenylalanine 1-methyl ester (neotame) as a sweetener in chewing gum compositions.
  • PARRIS-N ET AL "Encapsulation of Essential Oils in Zein Nanospherical Particles", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53 , relates to Encapsulation of Essential Oils in Zein Nanospherical Particles.
  • a method for microencapsulating an active ingredient(s) within an enteric matrix in an aqueous environment substantially free of organic solvents comprising:
  • microencapsulated particulate composition comprising:
  • a method for microencapsulating an active ingredient with an enteric matrix includes agitating or mixing a combination of water and an enteric material at a pH that forms an aqueous solution of the enteric material.
  • the combination is substantially free of organic solvents.
  • the enteric material includes and preferably is a combination of shellac and sodium caseinate.
  • a hydrophobic liquid is then added to the combination.
  • the hydrophobic liquid containing the active ingredients and combination is then agitated to create a coarse emulsion, followed by homogenization to create a fine and stable emulsion.
  • the emulsion is then acid titrated with an amount of acid to a pH at an isoelectric point of sodium caseinate effective to precipitate a particulate of the hydrophobic liquid homogenously dispersed throughout an enteric matrix of the shellac and sodium caseinate. Further, the particulate precipitate can be filtered, washed and dried to form a powder. In one embodiment a surface oil remover can be added to the precipitate after filtering to remove surface oil from the microencapsulated material.
  • one or more outer enteric coatings may be applied to the surface of the microencapsulated material.
  • the outer coating can include a combination of an enteric material and a plasticizer, such as a sugar alcohol (i.e., sorbitol).
  • the outer coating may be a combination of a first and second outer coating where the second outer coating can be applied after the first outer coating.
  • the second outer coating may be provided from a combination of an enteric material and a plasticizer, such as a sugar alcohol, that may be the same or different from the first outer coating.
  • Methods are provided for microencapsulating a hydrophobic liquid in an aqueous environment substantially free of organic solvents.
  • One method for microencapsulating a hydrophobic liquid is generally described in Figure 1 .
  • water, an enteric matrix material and an emulsifier are subjected to agitation until the enteric matrix material and emulsifier are combined with the water to form a solution 100.
  • the emulsifier and enteric matrix material can be added to the water together or separately, with either being added first.
  • the pH of the solution is generally greater than 7, and generally greater than about 7.1 to about 9.
  • a base such as sodium, ammonium or potassium hydroxide
  • a base such as sodium, ammonium or potassium hydroxide
  • the hydrophobic liquid is then added to the aqueous solution.
  • the aqueous solution containing the hydrophobic liquid is then mixed to form an emulsion and then acid titrated to precipitate out the hydrophobic liquid microencapsulated with the enteric matrix material.
  • FIG. 7 Another method for microencapsulating a hydrophobic liquid is generally described in FIG. 7 .
  • This alternative method is similar to the methods of FIG. 1 , but adds additional outer coatings of enteric materials.
  • the methods of FIG. 7 are particularly suited to be used with enteric matrix materials of shellac and sodium caseinate with the optional inclusion of an emulsifier (both shellac and sodium caseinate provide emulsification).
  • the methods of FIG. 7 may be used with other enteric matrix materials as well.
  • agitation or “agitated” generally refers to the use of a top mixer with impeller or a rotor/stator mixing device operating at a speed of less than about 10,000 RPM. Other mixing devices may also be employed.
  • substantially free of organic solvent generally refers to an amount of added organic solvent, such as isopropanol or ethanol or any other organic solvent, which is less than the amount of organic solvent required to enable solubilization of the enteric material under the processing conditions.
  • the amount of added organic solvent is less than about 0.1 percent by weight of the combination of water, emulsifier and enteric material.
  • organic solvent generally refers to a non-aqueous, hydrocarbon-based liquid.
  • the water is deionized water.
  • the enteric matrix material used herein is any food grade enteric polymer, or a combination of two or more food grade enteric polymers, provided it includes shellac and sodium caseinate.
  • the enteric matrix material is either shellac or zein or a combination thereof.
  • the ratio of enteric polymers, such as shellac to zein can be predetermined to achieve the desired release rate after ingestion, with a decreased release rate corresponding with an increased ratio of shellac to zein.
  • the shellac can be provided as an alkaline (pH > 7) aqueous solution, such as a water-based solution having a solid content of about 25 percent by weight or it can be prepared from refined, bleached and dewaxed shellac powder.
  • the shellac is substantially free of organic solvent, although it may contain trace amounts of organic solvents, such as isopropyl alcohol (such as can be included in commercial products), to act as a carrier for other ingredients in the shellac solution, such as methyl and propyl parabens.
  • organic solvents such as isopropyl alcohol (such as can be included in commercial products)
  • the prepared shellac solution does not contain any added organic solvents.
  • the enteric matrix material includes a combination of shellac and zein, with zein comprising at least about 5 percent of the enteric matrix material by dry weight. Due to differences in hydration and solubility of zein and shellac, particularly the solubility at varying pHs and rates of hydration and solubility, different ratios of shellac to zein provide different enteric dissolution properties as well as differing degrees of core material protection in the final product, such as beverages.
  • the enteric matrix material includes a combination of sodium caseinate and shellac.
  • the enteric matrix material consists essentially of shellac and sodium caseinate.
  • the enteric matrix material and optional emulsifier may be solubilized in water, in one form alkaline water, substantially free of an organic solvent.
  • the combination of the solubilized shellac and sodium caseinate provides an emulsification capability so that the addition of an emulsifier is not required in this approach.
  • the combination of shellac and sodium caseinate improves stability of the resulting microencapsulated hydrophobic liquid over the duration of the shelf life of the microencapsulated hydrophobic liquid.
  • the enteric matrix material and sodium caseinate are solubilized separately in separate aqueous solutions and then combined in a single solution.
  • a desired ratio of shellac to caseinate ranges from about 90:10 to about 10:90, in other cases the ratio ranges from about 30:70 to about 70:30, and in yet other cases the ratio ranges from about 40:60 to about 60:40.
  • the emulsifier described herein is any food grade emulsifier.
  • the emulsifier is polysorbate, polyglycerol ester, sucrose stearate, sucrose esters, proteins, lecithins or combinations thereof.
  • the methods herein combine water, an optional emulsifier, the enteric matrix materials and a hydrophobic liquid in a manner effective to microencapsulate the hydrophobic liquid in the enteric materials substantially free of organic solvents.
  • the methods use water in amounts from about 50 percent to about 95 percent of the combination by weight and, in some approaches, from about 70 to about 95 percent, and, in other approaches, from about 80 to about 90 percent.
  • the optional emulsifier is generally less than about 5 percent of the combination by weight, in some instances from about 0.01 to about 1 percent by weight, and, in other instances, about 0.01 to about 0.1 percent by weight of the combination.
  • the enteric material ranges from about 3 percent to about 35 percent by weight, in some approaches from about 3 to about 23 percent, and, in other approaches, from about 10 percent to about 15 percent by weight of the combination.
  • the hydrophobic liquid generally is in amounts of about 1 to about 15 percent by weight of the combination, and in other approaches, about 3 to about 6 percent by weight.
  • the water, enteric matrix material and optional emulsifier are combined 100 to form a solution.
  • a hydrophobic liquid is then added 200 to the combination and agitated to provide a coarse emulsion having a droplet size of more than about 10 micrometers.
  • the coarse emulsion is subjected to homogenization to create a fine, stable emulsion 300.
  • the fine, stable emulsion has a droplet size of less than about 10 micrometers.
  • the hydrophobic liquid is homogeneously dispersed in the form of fine droplets throughout.
  • the hydrophobic liquid is added in amounts ranging from about 1 to about 15 percent of the combination by weight. In other approaches, the hydrophobic liquid is added in an amount ranging from about 3 to about 6 percent of the combination by weight.
  • hydrophobic liquid generally refers to any non-polar, water insoluble or immiscible liquid, such as essential oils, functional oils, oil solubles and any other functional material.
  • homogenization or “homogenized” generally refers to the use of a rotor/stator mixing device operating at a speed greater than about 10,000 RPM or a valve homogenizer operating at a pressure of about 500 to about 10,000 psi. Other homogenization equipment may also be used.
  • the hydrophobic liquid can include any mixture of hydrophobic liquids and solids, such as solids mixed or combined therewith or dissolved or solubilized therein.
  • hydrophobic liquid can be selected to include materials which are desired to be released in the small intestine rather than the stomach due to pH sensitivity.
  • the hydrophobic liquid can include compositions described in U.S. Patent Publication No. 2008/0145462 to Enan
  • the hydrophobic liquid includes about 25 to about 35% by weight para-cymene, about 1 to about 10% by weight linalool, about 1 to about 10% by weight alpha-pinene, about 35 to about 45% by weight thymol, and about 20 to about 30% by weight soybean oil.
  • the hydrophobic liquid described herein can include an essential oil blend which possesses anti-parasitic properties.
  • the essential oil blend is organic compounds blended with food grade oil, i.e. soybean oil.
  • the organic compounds can include thymol and linalool.
  • the organic compounds include alpha-pinene and para-cymene.
  • one exemplary blend of an essential oil includes, by weight, about 17.5 percent soybean oil, about 8 percent alpha-pinene (liquid), about 44 percent para-cymene (liquid), about 5 percent linalool (liquid) and about 25.5 percent thymol (crystal).
  • the hydrophobic liquid may also include modified forms of the hydrophobic liquid, as described in provisional Patent Application Serial No. 61/422,439, filed December 13, 2010 , which is incorporated herein in its entirety by reference.
  • the hydrophobic liquid includes esters, such as esters of linalool and thymol, as described in Application Serial No. 12/479,444, filed June 5, 2009 , which is incorporated herein in its entirety by reference.
  • hydrophobic liquid examples include unsaturated and polyunsaturated OMEGA 3, other unsaturated and polyunsaturated lipids or fatty acids and triglycerides thereof, beta-carotene, and oil soluble vitamins, stomach irritants, or any other hydrophobic materials that are either sensitive to acidic pH conditions or impart strong undesirable taste.
  • the fine, stable emulsion is then acid titrated 400.
  • the emulsion is agitated.
  • Acid is titrated in an amount effective to decrease the pH below the matrix solubility point, such as a pH of about 7, causing phase separation and inducing precipitation of the enteric matrix material out of solution with the hydrophobic liquid being microencapsulated therein, thus creating a slurry of an aqueous solution and precipitate.
  • the acid titrating of the emulsion is carried out with an amount of acid to a pH at an isoelectric point of sodium caseinate effective to precipitate a particulate of the hydrophobic liquid homogenously dispersed throughout an enteric matrix of the shellac and sodium caseinate.
  • the slurry includes a particulate precipitate having a particle size from about 1 to about 1000 micrometers, in some cases about 10 to about 500 micrometers, and in yet other cases from about 75 to about 250 micrometers.
  • precipitation occurs at a pH ranging from about 3 to about 6.5, and in other approaches from about 3 to about 5, and in one approach at a pH of about 4.5.
  • the fine, stable emulsion of sodium caseinate and shellac is acid titrated to a pH corresponding to the insolubility at the isoelectric point of sodium caseinate, such as about 4.5 to about 4.6, which is below the solubility point of shellac.
  • the slurry may be allowed to settle, resulting in a clear division of the liquid or supernatant and the settled particulate.
  • enteric materials such as shellac, sodium caseinate and zein
  • enteric materials may cross-link to like particles or to one another to form a matrix, the hydrophobic liquid being microencapsulated within the matrix.
  • the hydrophobic liquid is homogeneously dispersed throughout the matrix.
  • the matrix further provides a seal for the hydrophobic liquid.
  • the acid used for acid titration 400 can be any food grade acid.
  • the acid is a weak food grade acid.
  • the acid may be citric acid.
  • the composition of the enteric matrix material affects the dissolution rate and the protection provided by the enteric matrix. As a result, the rate and amount of acid addition varies based on the enteric matrix materials used.
  • the slurry may be filtered 500 to produce a wet cake, then washed 600 and dried 700 to produce a dried cake.
  • both the particulate and the supernatant are both filtered 600 to produce a cake, then washed 600 and dried 700 to provide a dried cake.
  • the slurry or supernatant and particulate are filtered 600 to provide a wet cake. The wet cake is then washed, refiltered and rewashed prior to drying.
  • the surface oil on the outer surface of the particulate precipitate is less than about 1 percent by weight of the final product.
  • a surface oil remover may be added after filtering to aid in removing residual surface oil from the precipitate, as described in co-pending application serial no. 12/479,433, filed June 5, 2009 , which is incorporated herein in its entirety by reference. Further, the surface oil remover can also be added prior to the refiltering step.
  • the precipitate After the precipitate has been filtered and washed, the precipitate is dried to form a powder. Drying can be conducted at room temperature such that the powder has a moisture content of less than about 10 percent, and in some cases to a moisture content of about 5 to about 6 percent.
  • the powder can be pulverized to reduce the particle size of the powder precipitate, and then further dried to a moisture content of less than about 5 percent, such as with a fluidized bed dryer.
  • the resultant particles have a particle size ranging from about 1 to about 1000 micrometers, in some approaches from about 10 to about 500 micrometers, and in other approaches from about 75 to about 250 micrometers.
  • the temperature may be maintained between about 25C to about 70C, in some approaches between about 35 C to about 60C, and in other approaches between about 35C and about 45C.
  • the temperature may be maintained between about 4C to about 40C, in some cases about 4C to about 30C, and in other cases from about 15C to about 28C.
  • the microencapsulated hydrophobic liquid produced by the above described methods may have an increased payload.
  • Payload generally refers to the weight percentage of the functional ingredients in relation to the final particulate product.
  • the total payload generally refers to the total weight percentage of all the encapsulated functional ingredients, including the any carrier oil, in relation to the final particulate product. Therefore, an increase in payload corresponds to an increase in functional ingredient per a given amount of enteric matrix.
  • the resultant powder can be further processed, such as applying an outer coating around the enteric matrix particulate product 800.
  • the outer coating surrounds the enteric particulate product and any residual surface oil or functional ingredients on the surface of the particulate product.
  • the outer coating can improve the shelf life of the particulate product.
  • the efficacy of the coating as a shelf life extender depends on many variables, including the enteric material used for providing the enteric matrix.
  • the application of an outer coating can increase the shelf life of particulate product where sodium caseinate is used as an enteric matrix material.
  • the outer coating can include any food grade enteric polymer, or can include a combination of food grade enteric polymers and a plasticizer such as a sugar alcohol (i.e., sorbitol).
  • the outer coating may include a combination of two layers where a second outer coating 900 can be applied onto the first outer coating.
  • the second outer coating may also be any food grade enteric polymer, or a combination of a food grade enteric polymer and a plasticizer, such as a sugar alcohol (i.e., sorbitol).
  • the second outer coating may be the same or different form the first outer coating.
  • Each solution to prepare the first and second outer coatings can include about 5 percent to about 20 percent enteric material and about 1 percent to about 3 percent plasticizer, such as a sugar alcohol.
  • the final, coated microencapsulated particles can include between about I to about 15 percent by weight of each of the first and second coatings..
  • the outer coating materials can be applied to the enteric matrix by mixing, spraying or other suitable application 800 and 900. ( FIG. 7 ).
  • the outer coating materials are first solubilized in water.
  • a base can optionally be added to the solubilized outer coating material to increase the pH to greater than 7, in some cases between about 7.1 and about 12.
  • the solubilized material can then be atomized and sprayed onto the uncoated particulate product.
  • the enteric matrix can be coated via two different coating steps 800 and 900.
  • the first coating step 800 includes atomizing a solution including zein and sorbitol to coat the uncoated enteric matrix.
  • the first coating material may include from about 1 percent to about 20 percent zein and from about 1 percent to about 3 percent sorbitol.
  • the first coating material is solubilized in water, after which the pH is adjusted by adding a base material. For instance, an amount of a base, such as ammonium hydroxide, can be added to increase the pH in order to completely solubilize the zein, in some cases to a pH of about 9.5 to about 12.
  • the pH can then be increased in a two step addition by adding a second base material, such as sodium hydroxide.
  • the solubilized coating material can then be atomized and sprayed into a fluidized bed coater to coat the uncoated enteric matrix particulate product within the fluidized bed.
  • the second coating step 900 may include atomizing a solution of enteric material and plasticizer to coat the uncoated particles.
  • the enteric material of the second coating is not the same as the enteric material of the first coating.
  • the second enteric material may be shellac and the plasticizer is sorbitol.
  • the second outer coating material includes from about 1 percent to about 20 percent shellac and from about 1 percent to about 3 percent sorbitol.
  • the second coating material is then solubilized in water.
  • the solubilized second coating material can then be atomized and sprayed into a fluidized bed coater to coat the once-coated enteric matrix particulate product within the fluidized bed.
  • the first and second coatings each have coating thicknesses of about 1 micrometer to about 5 micrometers.
  • the final particle size of the coated particle is about 1 to about 1000 micrometers, in other cases about 10 micrometers to about 500 micrometers, in other cases from about 50 micrometers to about 300 micrometers, and in yet other cases from about 75 micrometers to about 250 micrometers. If desired, the coated matrix particles can then be sieved to meet the desired particle size.
  • Examples 1 to 11 are comparative examples.
  • Example #1 100 percent Shellac as the Enteric Matrix Material.
  • An essential oil blend was prepared by blending about 8 percent alpha-pinene (liquid), about 44 percent para-cymene (liquid), about 5 percent linalool (liquid), about 25.5 percent Thymol (crystal), and about 17.5 percent soybean oil. Mixing in a glass beaker with stirring bar was typically carried out until all of the Thymol crystals are dissolved.
  • a large beaker the following steps were carried out in the order specified: about 1200 g of deionized (DI) water was added to the beaker, and then about 300 g of the stock solution of about 25 percent shellac (MarCoat solution from Emerson Resources Inc.) was mixed into the DI water under agitated conditions such that the pH of solution ranges from about 7.2 to about 9. While agitating, about 0.8 g of polysorbate 85 was added and mixed for about 1-2 minutes for full dispersion. Next, about 35 g of an essential oil blend was slowly added under agitated conditions to form a coarse emulsion. Once the oil was dispersed, the mix was homogenized at about 12500 rpm for about 5 minutes using Fisher Scientific PowerGen 700D Homogenizing System with 200 millimeter x 25 millimeter Generator head.
  • DI deionized
  • shellac MarCoat solution from Emerson Resources Inc.
  • the emulsion was then subjected to agitation and, while mixing, about 2 percent citric acid solution was titrated in at a slow rate while monitoring the resultant change in pH. Titration continued until the pH reached about 4.4, after which SiO 2 (AB-D from Pittsburgh Plate Glass Industries) was added (about 5g SiO 2 , in about 200g water), and the slurry was mixed for about 15-20 minutes.
  • SiO 2 ABS-D from Pittsburgh Plate Glass Industries
  • the slurry was then filtered by pouring the slurry over a 200 mesh screen with 75 micrometer holes.
  • the particulates on the top of the screen were resuspended in about 1000 g water with about 3.5 g SiO2.
  • the slurry was mixed for about 30 to about 60 seconds and then re-filtered. The washing was repeated one more time as above, the filtrate was collected, spread on tray and allowed to dry at room temperature for overnight (to a moisture content of between about 5 to about 6 percent).
  • the payload generally refers to the weight percentage of the functional ingredients in relation to the final particulate product.
  • the total payload generally refers to the total weight percentage of all the functional ingredients, including the soybean oil, in relation to the final particulate product. Therefore, an increase in payload corresponds to an increase in functional ingredient per a given amount of enteric matrix.
  • the emulsion was then titrated with about 2 percent citric acid solution until pH reached about 4.4, and then about 75 g of SiO 2 was added and mixed in for about 20 minutes.
  • the slurry was then filtered using a 200 mesh (75 micrometer) screen.
  • the filter cake was re-suspended in about 20 lb of water with about 50 g SiO 2 , mixed for about 5 minutes, and then re-filtered on a 200 mesh screen.
  • the washing was repeated one more time, and the final filter cake was spread on a large tray for overnight drying at room temperature (about 20 to about 25 C).
  • the next day the product was pulverized in a warring blender, and then fluid bed dried at about 40C. Collected powder was sifted through a 35 mesh (500 micrometer) screen.
  • Figure 2 provides the compositional analysis.
  • Example # 3 Use of 100 percent Zein Powder (corn proteins) as the Enteric Matrix Material.
  • zein F4000 from Freeman Industries
  • DI water DI water
  • the zein was then dispersed in the water via agitation. Once the zein powder was completely dispersed, about 10 percent sodium hydroxide solution was slowly titrated into the dispersed zein until the pH reached about 11.3. At this pH, the zein powder was completely solubilized.
  • about 0.7 g of polysorbate 85 was added, agitated for about 1-2 minutes, and then about 30 g of the essential oil blend from Example 1 was added. The mixture was homogenized as in Example 1.
  • the emulsion was then titrated with about 2 percent citric acid solution (as in Example 1) until pH reached about 4.6. The slurry was mixed for about 15-20 minutes.
  • Example 2 Filtering and washing was conducted as in Example 1, except no SiO 2 was added. Filtrate was collected and dried on a tray at room temperature for overnight. Sample was analyzed for percent payload of each component and total payload.
  • the payload generally refers to the weight percentage of the functional ingredients in relation to the final particulate product.
  • the total payload generally refers to the total weight percentage of all the functional ingredients, including the soybean oil, in relation to the final particulate product.
  • Example # 4 Scalability of the Process using 100 Percent Zein as the Enteric Matrix Material.
  • sucrose ester S-1570 from Mitsubishi Kagaku Corporation, Tokyo, Japan
  • the sucrose ester was then dispersed in the tank by agitation.
  • about 750 g of zein powder was dispersed via agitation in the tank, followed by metering of about 10 percent sodium hydroxide solution into the tank while mixing until pH reached about 11.3.
  • the resulting solution was then mixed until the zein powder was completely dissolved.
  • about 400 g of the essential oil blend from Example 1 was slowly added. Once all the oil was dispersed, the mixture was homogenized for about 5 minutes to create an emulsion as in Example 1.
  • the emulsion was then titrated with about 2 percent citric acid solution under agitation until pH reached about 3.8.
  • the slurry was allowed to mix for about an extra 10 minutes.
  • the mixture was transferred into separate containers, allowed to stand for a few minutes so the precipitated particulates could settle at the bottom.
  • the supernatant was decanted onto a large 200 mesh screen followed by screening the remaining particulates.
  • the filtrate on top of the screen was re-suspended in about 9 kg of acidified water (pH about 3.5), containing about 20 g SiO 2 , mixed for a few minutes and then decanted and filtered. This washing step was repeated one more time, the rinse water containing about 20 g SiO 2 , after filtering the filter cake was collected, spread thin on a tray and allowed to dry overnight at room temperature (about 20 to about 25 C).
  • the semi-dry powder was pulverized and then fluid bed dried at about 40° C to target moisture (less than about 5 percent). Final product was sifted through a 35 mesh (500 micrometer) screen. See Figure 2 for the compositional analysis.
  • Example 5 Matrix Containing About 75 Percent Shellac & About 25 percent Zein
  • Example # 6 In Vitro Testing of Simulated Release in Stomach and Small Intestine
  • This example is intended to show the release rate and profile of actives from the matrix of the microcapsules from Examples 2, 4, and 5. Release from enteric microcapsule samples was evaluated by sequential simulation in a stomach simulation solution (about 10 mg/ml pepsin, about 2 mg/ml NaCl, pH about 2) for about 30 min followed by a small intestinal simulation solution (about 10 mg/ml pancreatin, about 2.4 mg/ml bile salt, pH about 6.8) for up to about 24 hr at about 37C. Samples were taken at pre-determined time intervals and analyzed for release of individual actives.
  • the release profile is different for the three compositions.
  • the release of the active materials from the essential oils continued to have a gradual increase over time but never reached complete release even after 12 hrs.
  • the release can be characterized as having a quicker release rate and higher total release when the matrix is made up of 100 percent zein (about 80 percent of the total payload is released at the first hour in the intestinal conditions) (see Figure 4 ).
  • the combination of the shellac and zein (See Figure 5 ) show a higher rate than 100 percent shellac, but lower than 100 percent zein, and the release seem to be sustained at a slow rate with a maximum after 6 hours.
  • Example # 7 This example demonstrates the microencapsulation of oil blend containing two esterified components (Thymol acetate and Linalool acetate in combination with alpha-pinene, para-cymene, and canola oil)
  • zein powder In a beaker, about 2400 g of water was added and then, with agitated mixing, about 7.5 g of zein powder was dispersed in the water. About 10 percent sodium hydroxide solution was metered into the aqueous solution until pH reached about 11.3 (to solubilize the zein powder). Next, about 570 g of about 25 percent shellac solution and about 1 g sucrose stearate (S-1570) were added, followed by about 70 g of an essential oil blend (about 18.8 percent canola oil, about 8.6 percent alpha-pinene, about 39.8 percent para-cymene, about 5.4 percent Linalool acetate and about 27.4 percent Thymol acetate), which was added slowly to the mix.
  • an essential oil blend about 18.8 percent canola oil, about 8.6 percent alpha-pinene, about 39.8 percent para-cymene, about 5.4 percent Linalool acetate and about 27.4 percent Thymol acetate
  • the emulsion was then homogenized (as in Example 1) using a Fisher Scientific PowerGen 700D Homogenizing System with 200 millimeter x 25 millimeter Generator head at about 15000 rpm for about 4 minutes, then at about 20000 rpm for about 1 minute.
  • the emulsion was then titrated with about 3 percent citric acid solution to pH about 4. Then, about 280 g of about 10 percent sodium chloride solution and about 15 g Si02 was added and allowed to mix for about 30 minutes. The slurry was then filtered and washed similar to that described in Example 1. The washed filter cake was spread on a tray to dry overnight, and then further dried in a fluid bed dryer at about 40C, powder was sifted and product passing through 35 mesh (500 micrometers) size was collected. Final moisture was about 4.7 percent.
  • the release rate is shown in Figure 6 .
  • the payload generally refers to the weight percentage of the encapsulated functional ingredients and oil in relation to the final particulate product.
  • the total payload generally refers to the total weight percentage of all the encapsulated functional ingredients and canola oil, in relation to the final particulate product.
  • Example # 8 Preparing Cream Wafer with Microencapsulated Essential Oil Wafer Filling
  • White cream filling was prepared by mixing in a Hobart mixer. First about 750 g of pre-melted San-Trans 39 Shortening plus about 0.5 g of liquid soy lecithin was mixed with confectionary sugar (powder sugar), until smooth and homogeneous. Filling was transferred into a container and cooled down for later use.
  • Wafer cracker sheets were purchased from local grocery store. About 97.8 g of cream filling was softened by warming up in a microwave oven. To the filling, the following was added: about 1.5 g of microencapsulated material, about 0.15 g citric acid, about 0.5 g Lemon oil flavor, one drop of beta-carotene for yellow color. The filling was spread on the cracker sheet (about 1-2 millimeters thick), and then another sheet was applied onto the top. The cracker sheet sandwich was then cooled in a refrigerator (about 0 to about 5 C) for about 30 minutes, and then it was cut to different sizes (cracker size). A similar formulation, double and triple layer crackers were also prepared. Other flavor varieties were also evaluated including chocolate and fruit flavors.
  • Example 9 Cracker Sandwich with Filling Including the Microencapsulated Material
  • a cracker sandwich with microencapsulated powder incorporated into the filling was prepared as follows:
  • the melted fat was poured onto the dry blend in the Hobart Mixer, and allowed to mix for at least about 5 minutes (to form a homogeneous mix).
  • the filling was transferred into a container and used as a stock filling.
  • Cracker sandwich about 100 g of cheese filling was warmed up in a microwave oven for about 30 seconds and to the softened filling, about 1.4 g of the microencapsulated material was mixed in, and also various seasoning and flavor blends. About 18 g of the filling was sandwiched between two crackers, and allowed to cool down. Different flavor varieties of cracker sandwiches were evaluated including, nacho, taco, Italian herb, and oriental seasoning. Filling was also evaluated with different type of crackers, including Saltine, Ritz and others. When evaluated, the crackers containing microencapsulated essential oil were pleasantly acceptable.
  • Example 10 This example demonstrates the encapsulation of the essential oils, followed by surface oil removal as disclosed in co-pending application serial no. 12/479,433.
  • zein powder In a beaker, about 2400 g of water was added in and then, with overhead low shear mixing, about 37.5 g of zein powder was added and dispersed throughout the water. Next, about 10% sodium hydroxide solution was metered into the aqueous solution until pH reached about 11.3 (to solubilize the zein powder). Next, about 450 g of 25% shellac solution was added, followed by about 1.4 g sucrose stearate (S-1570), and then about 80 g essential oil blend (about 13% canola oil, about 10% alpha-pinene, about 25% Para-cymene, about 12% Linalyl acetate, about 40% Thymol acetate) was added slowly to the mix. The emulsion was then homogenized using an IKA Works T25 Basic Ultra Turrex with 200 millimeter x 20 millimeter Generator head at about 17,500 rpm for about 1 minute, then at about 24,000 rpm for about 5 minutes.
  • the emulsion was then titrated with about 3% citric acid solution until the pH reached about 3.8. Then, about 15 g SiO 2 (Flo Guard FF, average size of about 18 micrometers) was added in and allowed to mix for about 30 minutes. The slurry was then filtered by pouring over a filter cloth with greater than about 5 micrometers holes. The particulates on the filter cloth were then resuspended into about 2000 g water containing about 0.5 g citric acid, about 0.5 g sucrose stearate (S-1570), and about 7. 5 g SiO 2 (Flo Guard FF). The slurry was mixed for about 15 minutes and then re-filtered. The washing was repeated one more time as above, then filter cake was collected. The filter cake was then pressed by placing in a 30 micrometers filter bag in a press box and squeezing in a cheese press at about 20 psi for about 20 minutes to remove more of the water. The press cake moisture was about 18.8%.
  • the press cake was mixed with about 50 g SiO 2 (Flo Guard FF) in a 5 quart Hobart mixer with a whip at speed set at 1 for about 5 minutes.
  • the material from the Hobart mixer was ground in a Fitz Mill Model DA SO6 Comminutor with hammers forward at the highest speed using a 1532-0020 perforated plate.
  • the ground material was tumbled using jar tumblers for about 60 minutes.
  • the batch was then dried in a Uni-Glatt Fluid Bed Dryer at about 40°C for about 20 minutes. The dried batch was screened and only particles between 75-250 micrometers were collected. Note that the payload generally refers to the weight percentage of the encapsulated functional ingredients in relation to the final product.
  • the total payload generally refers to the total weight percentage of all the encapsulated functional ingredients in relation to the final product.
  • Example # 11 Preparing a Powdered Beverage with Microencapsulated Material
  • Powdered soft drinks such as fruit based type are suitable for the delivery of enteric active compounds for several reasons: 1) The powdered drink can easily be dry blended with microencapsulated material, and provide shelf stability for extended period of time, 2) when reconstituted, the beverage has an acidic pH (similar to stomach pH), no early release, and, therefore, no adverse effect on taste, 3) Beverages, once prepared, are typically consumed within a very short period of time.
  • the orange type powdered beverage was sweetened with sugar and artificial sweetener and was dry blended with the microencapsulated essential oil from example # 10.
  • 0.35g of carboxy methyl cellulose (Aqualon 7HXF) was added to the dry blend to provide extra viscosity and better suspendability.
  • the dry blend was reconstituted into about 200 ml of cold water.
  • the beverage was tasted after about 5 and about 60 minutes after reconstitution by an informal sensory panel. Testing by a sensory panel demonstrated successful masking of the essential oil blend in the orange type beverage.
  • Example # 12 A coated, microencapsulated product was prepared including an essential oil blend having an enteric matrix combination of shellac and caseinate.
  • the matrix solution was prepared in two parts. First, a shellac solution including about 480g of a 25% shellac solution was diluted with about 1600g of DI water. The 25% shellac stock solution was pre-prepared ahead of time. The pH of the solution was about 7.5. Next, a caseinate solution was prepared with an overhead mixer. In particular, about 180g of sodium caseinate was hydrated in about 1800g DI water. Mixing was carried out at low speed until all powder was completely hydrated. The caseinate solution was then slowly added to the shellac solution under gentle mixing resulting in a final pH of about 7.3.
  • an essential oil blend (about 70% Thymyl Octanoate, about 15% Linalyl acetate, about 10% para-cymene, about 5% alpha-pinene) was added slowly to the mixed solution. Once all the oil was added, high shear (rotor and stator type) was applied to prepare a coarse emulsion. The coarse emulsion was then high pressure-homogenized using a dual stage homogenizer at about 500 psi and about 5000 psi (first and second stage respectively) to provide a fine emulsion.
  • an essential oil blend about 70% Thymyl Octanoate, about 15% Linalyl acetate, about 10% para-cymene, about 5% alpha-pinene
  • the fine emulsion was titrated using about a 12% citric acid solution while mixing. Titration of the fine emulsion continued until the pH reached about 4.5, at which time most of the emulsified particulates were precipitated out with the actives entrapped within.
  • the particulates were filtered out using filter press at about 40 psi for about 30 minutes to form a filter cake.
  • the cake was then pulverized in a food processor.
  • the pulverized particulates were fluid bed dried (pre dried) at about 60 degrees C for about 10 minutes, then fine ground using a 0.75 millimeter screen. The final grind was dried at about 60 degrees C for about 40 minutes. The next day, the particulates were further dried at about 40 degrees C for about 20 minutes. Dried particulate was sifted and the fraction between 75 and 200 micrometers was collected.
  • the sifted, dried particulate was then further coated.
  • about 200g of base, uncoated particulate was added to a fluidized bed (Mini-Glatt) and warmed to about 40C for about 15 minutes.
  • two coating solutions were prepared.
  • the first solution was about 22.5g of zein, about 2.5g Sorbitol and about 130g water.
  • ammonium hydroxide was added until the pH increased to about 9.5.
  • sodium hydroxide was added until the pH increased to about 10.5.
  • Sufficient water was added to reach about 15% solids in the first solution.
  • the first solution was pumped into the 0.8 millimeter atomizing nozzle at about 1.2 g/minute with an atomization pressure of about 2 bars. After the first solution was pumped into the Mini-Glatt, the unit was stopped to clean the nozzle and restarted at about 40C.
  • a second solution including about 90g of about 25% shellac solution, about 2.5g sorbitol and about 74.2g water was prepared and mixed until the sorbitol was fully dissolved.
  • the second solution (shellac/sorbitol) was then pumped into the 0.8 millimeter atomizing nozzle at about 1.1g/minute with an atomization pressure of about 2 bars.
  • the particles were left to fluidize for about 10 minutes at about 40C to fully dry them.
  • the coated particles were then sieved to about 75 to about 200 micrometers and submitted for payload and surface/free oil analysis shown below.
  • the payload generally refers to the weight percentage of the encapsulated functional ingredients in relation to the final particulate product.
  • the total payload generally refers to the total weight percentage of all the encapsulated functional ingredients in relation to the final particulate product.
  • the total surface oil generally refers to the weight percentage of functional ingredients on the surface of the particles in relation to the final particulate product weight. % alpha-Pinene % para-Cymene % Linalyl acetate % Thymyl Octonoate Total Payload Payload 0.78 1.4 2.2 12.8 17.5 Total Surface Oils - 0.5%
  • Example # 13 Preparation of Powder Beverage with Coated Microcapsules.
  • Coated microencapsulated essential oil powder from Example 12 was dry blended with a fruit flavored powder beverage (Orange flavor & Mango).
  • the powder beverage was then sweetened with both sugar and an artificial sweetener. More particularly, a single serving amount of about 7g of powder beverage was dry blended with 0.5g of the coated microencapsulated essential oil powder.
  • the powder was then hydrated in about 200ml of cold water.
  • the product was sensory evaluated by an informal sensory panel (12 people). The informal sensory panel reported that the beverage had a very refreshing fruity and tangy taste with no noticeable off flavor. The product was also tasted after about 30 and about 45 minutes, with no change in flavor profile.
  • Example # 14 Stability of capsules over shelf life.
  • Coated microencapsulated essential oil powder from Example 12 was packaged into foil type packaging.
  • about 15 grams of coated microencapsulated essential oil powder were includes in each foil-type pouch.
  • the pouches were heat sealed and then stored at either refrigerated temperatures (about 5 C) or in accelerated storage chamber (about 32 C and about 80% RH).
  • the coated microencapsulated essential oil powder was taken out of storage at different time intervals (every 2 weeks) for sensory and analytical evaluation.
  • the coated microencapsulated essential oil powder was dry-blended with a powder beverage as described in Example 13. The dry-blended mixture was then hydrated in water to produce a beverage product. The beverage product was tasted by the same informal panel.
  • the resulting beverage products (were acceptable (i.e., no off flavor, and having a pleasant and refreshing taste as compared to a beverage without the coated microencapsulated essential oil powder) after the coated microencapsulated essential oil powder was stored for up to about 12 weeks of accelerated shelf life (with one week in accelerated storage believed to be equivalent to one month at ambient storage). Additionally, the prepared beverage product was analyzed for active ingredient within the beverage product that might have leaked out of the microcapsules. The tests showed a change of less than 1 ppm of active ingredient within the beverage products during the duration of the study. This very low level of free active ingredient did not have an impact on the product sensory attributes.
  • Example # 15 In Vitro Testing of Simulated Release in Stomach and Small Intestine
  • Coated microencapsulated essential oil powder from Example 12 was treated into simulated In Vitro. Release from enteric microcapsules was evaluated by sequential simulation in stomach simulation solution (about 10 mg/ml pepsin, about 2 mg/ml NaCl, pH about 2) for about 30 min followed by small intestinal simulation solution (about 10 mg/ml pancreatin, about 2.4 mg/ml bile salt, pH about 6.8) for up to about 24 hr at about 37C. Samples were taken at pre-determined time intervals and analyzed for release of individual actives.
  • Figure 8 illustrates the enteric release properties of the matrix. A minimum release was observed during the first 30 minutes of digestion at a pH below about 4 in simulated stomach conditions. The observed release increased up to about 70% within about 3 hours of digestion in simulated intestinal conditions. Release continued in simulated intestinal conditions to about 90% after about 25 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
EP11808505.9A 2010-12-22 2011-12-19 Novel preparation of an enteric release system Active EP2654737B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/976,614 US8859003B2 (en) 2009-06-05 2010-12-22 Preparation of an enteric release system
PCT/US2011/065828 WO2012087927A1 (en) 2010-12-22 2011-12-19 Novel preparation of an enteric release system

Publications (2)

Publication Number Publication Date
EP2654737A1 EP2654737A1 (en) 2013-10-30
EP2654737B1 true EP2654737B1 (en) 2018-02-21

Family

ID=45478561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11808505.9A Active EP2654737B1 (en) 2010-12-22 2011-12-19 Novel preparation of an enteric release system

Country Status (13)

Country Link
US (1) US8859003B2 (ru)
EP (1) EP2654737B1 (ru)
JP (1) JP2014502502A (ru)
KR (1) KR20140005924A (ru)
AR (1) AR084524A1 (ru)
AU (1) AU2011349501A1 (ru)
BR (1) BR112013015981B1 (ru)
CA (1) CA2822795A1 (ru)
MX (1) MX2013007277A (ru)
NZ (1) NZ612501A (ru)
RU (1) RU2013133411A (ru)
TW (1) TW201249354A (ru)
WO (1) WO2012087927A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064836B2 (en) 2012-08-03 2018-09-04 Tyratech, Inc. Antiparasitic compositions and methods
US8859005B2 (en) * 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
MX2016002787A (es) 2013-09-12 2016-05-26 Intercontinental Great Brands Llc Composicion de goma de mascar que comprende un saborizante microencapsulado en una matriz que comprende proteina.
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
WO2017168426A1 (en) * 2016-03-30 2017-10-05 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
ES2963955T3 (es) 2017-05-09 2024-04-03 Gea Mechanical Equipment Gmbh Aparato y método para tratar productos lácteos
US11793209B2 (en) 2017-05-09 2023-10-24 Gea Mechanical Equipment Gmbh Malaxation apparatus for the production of virgin olive oil
PL3621458T3 (pl) 2017-05-09 2021-12-13 Gea Food Solutions Bakel B.V. Aparat i sposób ogrzewania oleju do smażenia za pomocą technologii stałej energii RF
RU2019139053A (ru) * 2017-05-09 2021-06-09 Геа Фуд Сольюшнс Бакел Б.В. Установка и соответствующие промышленные применения с использованием технологии на основе твердотельных рч-источников энергии
ES2966363T3 (es) 2017-05-09 2024-04-22 Gea Food Solutions Bakel Bv Aparato de descongelación y método para descongelar una sustancia
IT202000030992A1 (it) 2020-12-16 2022-06-16 Tech Scientific S R L Sistema per il rilascio controllato di principi attivi

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010953A (en) * 1961-11-28 Certification of correction
US2464204A (en) * 1946-06-28 1949-03-15 Baker Irvin Method and means for removing oil and oily substances from solid or water surfaces
US2727833A (en) * 1950-11-03 1955-12-20 American Cyanamid Co Capsule finishing process
NL246986A (ru) * 1959-01-02 1900-01-01
DE1251273B (de) * 1961-12-22 1967-10-05 The National Cash Register Company, Dayton, Ohio (V. St. A.) Herstellen kleiner Kapseln durch Senken des pH-Wertes von Dispersionen
JPS5312473B1 (ru) * 1971-05-24 1978-05-01
JPS5210427B2 (ru) * 1972-07-19 1977-03-24
SU447163A1 (ru) 1972-12-22 1974-10-25 Институт Физической Химии Ан Ссср Способ микрокасулировани не смешивающихс с водой жидкостей
JPS52152876A (en) 1976-06-15 1977-12-19 Fuji Photo Film Co Ltd Production of oil-containing microcapsule
US4428841A (en) 1981-01-27 1984-01-31 Engineering Specialties, Inc. Offshore pollution prevention
US4518458A (en) * 1982-09-17 1985-05-21 Hanover Research Corporation Process for removing light oil from solids
WO1984003201A1 (en) 1983-02-18 1984-08-30 Wrigley W M Jun Co Shellac encapsulant for active ingredients in chewing gum
US4601863A (en) * 1984-02-09 1986-07-22 Kanzaki Paper Manufacturing Co., Ltd. Process for producing powder of microcapsules
US4702798A (en) * 1984-12-19 1987-10-27 Hanover Research Corporation Process for recovering dry solids from aqueous solids mixtures
JPS62129141A (ja) * 1985-11-29 1987-06-11 Fuji Photo Film Co Ltd マイクロカプセルの製造方法
FR2608456B1 (fr) 1986-12-18 1993-06-18 Mero Rousselot Satia Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention
JPS63268777A (ja) * 1987-04-25 1988-11-07 Kanzaki Paper Mfg Co Ltd マイクロカプセルインキ組成物
US4895725A (en) 1987-08-24 1990-01-23 Clinical Technologies Associates, Inc. Microencapsulation of fish oil
US5051305A (en) * 1988-12-30 1991-09-24 Arcade, Inc. Stabilized perfume-containing microcapsules and method of preparing the same
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5146758A (en) * 1991-03-04 1992-09-15 Herman Norman L Process of producing soft elastic gelatin capsules
JPH04330934A (ja) 1991-05-02 1992-11-18 Tokai Carbon Co Ltd 炭素系油吸収材および固形燃料
JP2964181B2 (ja) 1991-07-11 1999-10-18 花王株式会社 浴用剤組成物
US5164210A (en) * 1991-10-08 1992-11-17 Wm. Wrigley Jr. Company Zein/shellac encapsulation of high intensity sweeteners in chewing gum
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
EP0633733B2 (en) 1992-03-30 1999-12-29 Givaudan Roure (International) S.A. Heat-stable and fracturable spray-dried free-flowing flavor oil capsules, method of making and using in foods
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5643595A (en) * 1992-11-24 1997-07-01 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
MY111234A (en) * 1993-09-06 1999-09-30 Merpro Tortek Ltd Liquid / solid separation.
JPH0826930A (ja) 1994-07-11 1996-01-30 Kanebo Ltd 固型メークアップ化粧料
US5601760A (en) * 1994-09-01 1997-02-11 The Regents Of The University Of California, A California Corporation Milk derived whey protein-based microencapsulating agents and a method of use
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
DE69726514T2 (de) 1996-03-21 2004-09-23 Nippon Shokubai Co. Ltd. Verfahren zur herstellung von wärmespeichermaterialien
US20030077317A1 (en) 1996-06-25 2003-04-24 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
EP1369043B1 (en) * 1996-10-09 2010-05-26 Givaudan SA Use of beads as food additives
JPH10273650A (ja) 1997-01-31 1998-10-13 Kiyoueishiya:Kk 被処理油の処理方法及び固形燃料
US20020173522A1 (en) * 1997-03-26 2002-11-21 Redmon Martin P. Pharmaceutical compositions comprising norastemizole
RU2238719C2 (ru) 1997-10-14 2004-10-27 Берингер Ингельхайм Фармасьютикалс, Инк. Способ обработки капсул и сухих порошковых фармацевтических препаративных форм
US5958388A (en) * 1997-10-29 1999-09-28 Franks; James W. Material and method for removing sebum from human skin
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6143170A (en) * 1998-01-27 2000-11-07 Briggs; David L. Oil recovery system
DE19858253A1 (de) * 1998-12-17 2000-06-21 Aventis Pharma Gmbh Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
WO2000036924A1 (en) 1998-12-18 2000-06-29 The Nutrasweet Company N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER AS A SWEETENER IN CHEWING GUM
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19920816A1 (de) * 1999-05-05 2000-11-09 Aventis Pharma Gmbh Cephaibole, neue Antiparasitika aus Acremonium tubakii, Verfahren zu ihrer Herstellung und Verwendung derselben
BR0012673B1 (pt) * 1999-07-20 2011-01-25 partìcula de óleo encapsulada, processo para preparação da mesma, e composição de limpeza granular ou seu componente contendo uma partìcula de óleo encapsulada.
CA2380449A1 (en) * 1999-08-17 2001-02-22 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
EP1112740A1 (de) * 1999-12-30 2001-07-04 Greither, Peter Verwendung eines Polyglycerine enthaltenden wasserlöslichen Mittels
FR2814380B1 (fr) * 2000-09-25 2002-11-08 Serobiologiques Lab Sa Poudre de microcapsules et procede d'obtention
GB0027047D0 (en) * 2000-11-06 2000-12-20 Ici Plc Process for reducing the concentration of undesired compounds in a composition
EP1331946A2 (de) 2000-11-09 2003-08-06 Jörg-Peter Schür Synergistisches, aromastoffhaltiges arzneimittel mit antagonistischer, regenerativer und/oder protagonistischer dekontaminativer wirkung
AU9133401A (en) * 2000-11-28 2002-05-30 Rohm And Haas Company Hydrophobic absorbing polymers and process
DE60134421D1 (de) * 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
AU2002216359A1 (en) * 2001-02-27 2002-09-12 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
WO2002067874A1 (fr) * 2001-02-28 2002-09-06 Kao Corporation Produits cosmétiques
WO2002097142A1 (en) 2001-05-30 2002-12-05 Nippon Steel Corporation Device and method for treating oil-adhered particles
JP2003012526A (ja) 2001-06-27 2003-01-15 Sunstar Inc 有用生菌内包製剤
TW200300140A (en) * 2001-11-14 2003-05-16 Novartis Ag Organic compounds
DE10164110A1 (de) * 2001-12-24 2003-07-10 Dragoco Gerberding Co Ag Mononuklear gefüllte Mikrokapseln
US20050100640A1 (en) * 2002-02-11 2005-05-12 Pearce Tony M. Microcapsule edibles
WO2003069993A1 (en) * 2002-02-20 2003-08-28 Pharmessen Scientific, Inc. Antimicrobial therapeutic compositions and methods of use
US20030175403A1 (en) * 2002-03-14 2003-09-18 Gurin Michael H. Potentiated bioactive additives and method of use
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20030228369A1 (en) * 2002-05-06 2003-12-11 Kuhrts Eric Hauser Process for conversion of high viscosity fluids and compositions thereof
JP4312423B2 (ja) 2002-06-14 2009-08-12 ピジョン株式会社 腸溶性カプセル剤
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US6653288B1 (en) * 2002-09-30 2003-11-25 Virbac S.A. Injectable anthelmintic compositions and methods for using same
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP1585592A1 (en) * 2002-12-18 2005-10-19 Unilever N.V. Complex coacervate encapsulate comprising lipophilic core
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050287276A1 (en) * 2003-01-22 2005-12-29 Durafizz, Llc Microencapsulation for sustained delivery of carbon dioxide
US7140567B1 (en) * 2003-03-11 2006-11-28 Primet Precision Materials, Inc. Multi-carbide material manufacture and use as grinding media
JP2004310050A (ja) * 2003-03-26 2004-11-04 Daicel Chem Ind Ltd マイクロカプセル及びその製造方法
US7622269B2 (en) * 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
EP2533046A1 (en) * 2003-04-24 2012-12-12 Tyratech, Inc. Screening method for compositions for controlling insects
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
US20050123603A1 (en) * 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
EP1675571A2 (en) * 2003-09-30 2006-07-05 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
GB0402677D0 (en) * 2003-11-06 2004-03-10 Novartis Ag Organic compounds
US9592201B2 (en) * 2003-11-21 2017-03-14 Commonwealth Scientific And Industrial Research Organisation Gi track delivery systems
EP1541121B1 (en) * 2003-12-11 2007-03-21 Rohm And Haas Company System and process for releasing encapsulated active ingredients
CA2488981C (en) * 2003-12-15 2008-06-17 Rohm And Haas Company Oil absorbing composition and process
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US20050191328A1 (en) 2004-02-26 2005-09-01 Toshiya Taniguchi Make-up composition
AU2005231479C1 (en) * 2004-04-05 2012-03-15 Sunovion Pharmaceuticals Inc. (R,R)-formoterol in combination with other pharmacological agents
US20060147503A1 (en) * 2004-12-30 2006-07-06 3M Innovative Properties Company Oil absorbent wipe with high crumpability
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2614409C (en) * 2005-07-07 2014-05-20 Nanotherapeutics, Inc Process for milling and preparing powders and compositions produced thereby
WO2007025244A2 (en) * 2005-08-25 2007-03-01 Houle Philip R Treatment systems for delivery of sensitizer solutions
EP2664337B1 (en) * 2005-09-27 2019-08-14 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2007044437A2 (en) 2005-10-07 2007-04-19 The Government Of The Usa, As Represented By The Secretary Of The Department Of Health And Human Services Octanol formulations and methods of treatment using the same
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
CA2670355A1 (en) * 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20070148459A1 (en) * 2005-12-28 2007-06-28 Kimberly-Clark Worldwide, Inc. Microencapsulated delivery vehicles
JP4959189B2 (ja) 2005-12-28 2012-06-20 ライオン株式会社 ソイルリリースポリマー含有粒子、ソイルリリースポリマー含有粒子の製造方法、粒状洗剤組成物
US7442439B2 (en) * 2005-12-28 2008-10-28 Kimberly-Clark Worldwide, Inc. Microencapsulated heat delivery vehicles
US8753676B2 (en) * 2006-02-15 2014-06-17 Botanocap Ltd. Applications of microencapsulated essential oils
MX2008010547A (es) 2006-02-15 2009-01-27 Botanocap Ltd Aplicaciones de aceites esenciales microencapsulados.
MX2008016453A (es) * 2006-06-27 2009-05-15 Tyratech Inc Composiciones y metodos para tratar infecciones parasitas.
GB0613396D0 (en) 2006-07-06 2006-08-16 Harris Mike Process for removing oil from particulate matter
JP5066852B2 (ja) 2006-07-10 2012-11-07 日本化成株式会社 油分含有固形尿素中の油分除去方法
EP2048944A4 (en) * 2006-07-17 2012-06-27 Tyratech Inc COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
US20080207766A1 (en) * 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US9155703B2 (en) * 2007-03-12 2015-10-13 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
EP3369427B1 (en) * 2007-12-27 2021-10-13 TyraTech, Inc. Synergistic antiparasitic compositions and screening methods
US8691256B2 (en) * 2008-03-19 2014-04-08 Tyratech, Inc. Pest control compositions and methods
WO2010115065A2 (en) * 2009-04-03 2010-10-07 Tyratech, Inc. Methods for pest control employing microemulsion-based enhanced pest control formulations
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System

Also Published As

Publication number Publication date
RU2013133411A (ru) 2015-01-27
WO2012087927A1 (en) 2012-06-28
US8859003B2 (en) 2014-10-14
AU2011349501A1 (en) 2013-07-18
MX2013007277A (es) 2014-02-06
EP2654737A1 (en) 2013-10-30
CA2822795A1 (en) 2012-06-28
JP2014502502A (ja) 2014-02-03
TW201249354A (en) 2012-12-16
BR112013015981B1 (pt) 2021-06-22
NZ612501A (en) 2014-12-24
BR112013015981A2 (pt) 2018-07-10
US20110159103A1 (en) 2011-06-30
CN103429231A (zh) 2013-12-04
AR084524A1 (es) 2013-05-22
KR20140005924A (ko) 2014-01-15

Similar Documents

Publication Publication Date Title
EP2654737B1 (en) Novel preparation of an enteric release system
US8765030B2 (en) Preparation of an enteric release system
Chen et al. Coencapsulation of (−)-Epigallocatechin-3-gallate and quercetin in particle-stabilized W/O/W emulsion gels: Controlled release and bioaccessibility
EP2552233B1 (en) Preparation of solid capsules comprising flavours
US20100159079A1 (en) Encapsulate and Food Containing Same
US8465835B2 (en) Capsules
US20100158984A1 (en) Encapsulates
JP2012051840A (ja) ポリフェノール含有タンパク質の製造方法、ポリフェノール含有タンパク質及びその用途
Hamad et al. A novel approach to develop spray‐dried encapsulated curcumin powder from oil‐in‐water emulsions stabilized by combined surfactants and chitosan
EP1879470B1 (en) Fat, wax or oil-based food ingredient comprising encapsulated flavors
JPH07101882A (ja) 水溶性ヘミセルロースを含有する製剤
US8859005B2 (en) Enteric delivery of functional ingredients suitable for hot comestible applications
Kailasapathy Bioencapsulation technologies for incorporating bioactive components into functional foods
JPH07101881A (ja) 水溶性ヘミセルロースを含有する製剤
JPH0779712A (ja) 水溶性ヘミセルロースを含有する製剤
CN103429231B (zh) 肠释放系统的新制剂
JP2602335B2 (ja) フレーバー製剤
JPH0769865A (ja) 水溶性ヘミセルロースを含有する製剤
Boxall et al. Assessment of the potential use of nanomaterials as food additives or food ingredients in relation to consumer safety and implication for regulatory controls

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160914

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 13/00 20060101ALI20170830BHEP

Ipc: A61K 31/045 20060101ALI20170830BHEP

Ipc: A61K 31/015 20060101ALI20170830BHEP

Ipc: A61K 9/50 20060101AFI20170830BHEP

Ipc: A61K 8/11 20060101ALI20170830BHEP

INTG Intention to grant announced

Effective date: 20170919

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 970950

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011045864

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180221

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 970950

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180521

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180521

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011045864

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111219

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180621

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230329

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231227

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231229

Year of fee payment: 13

Ref country code: CH

Payment date: 20240101

Year of fee payment: 13